Agrippal is a clear colourless suspension for injection. It is an egg-grown, inactivated influenza virus vaccine based on isolated surface antigens of A and B strains of influenza virus. The antigen composition and strains for the 2016-17 influenza season corresponds to the following types:
- A/Michigan/45/2015 (H1N1)pdm09-like strain (A/Singapore/GP1908/2015, IVR-180) 15 micrograms HA
- A/Hong Kong/4801/2014 as the (H3N2)- like strain (A/Hong Kong/4801/2014, NYMC X-263B) 15 micrograms HA**
- B/Brisbane/60/2008- like strain (B/Brisbane/60/2008, wild type) 15 micrograms HA** Per 0.5 ml dose
Agrippal is indicated for the prevention of influenza caused by Influenza Virus, Types A and B.
- Adults and children from 36 months: 0.5 mL.
- Children 6 months to 35 months of age: 0.25 mL.
- For children less than 9 years of age who are receiving influenza vaccine for the first time, a second dose is recommended after an interval of at least 4 weeks.
Agrippal should not be administered to subjects with a known hypersensitivity to the active substance, to any of the excipients and to eggs, chicken proteins, kanamycin, neomycin, formaldehyde, barium sulfate, cetrimonium bromide (CTAB) or Polysorbate 80, or to anyone who has had an anaphylactoid reaction to a previous influenza vaccination. Immunisation should be postponed in patients with an acute severe febrile illness (fever > 38.5°C). The presence of a minor illness with or without fever should not contraindicate use of Agrippal.